Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1523541
This article is part of the Research Topic Covalent Drugs: A Century of Progress in Disease Treatment View all articles

Rare Skin Adverse Reactions Induced by Osimertinib: a case report and literature review

Provisionally accepted
Ye Zhang Ye Zhang 1Mingzhu Ling Mingzhu Ling 2*Min Wang Min Wang 1Ye Chen Ye Chen 2Liting Zhang Liting Zhang 2
  • 1 Department of Pharmacy, Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, China
  • 2 Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in the treatment of EGFR mutation-positive advanced non-small cell lung cancer. Osimertinib-induced cutaneous vasculitis is a rare skin adverse reaction. We present a case study of a 49-year-old female who developed palpable purpura on her lower extremities on the 11th day of osimertinib treatment. Systemic involvement was not observed in the test results. The multidisciplinary team considered the clinical presentation of purpura as a potential case of cutaneous vasculitis. Osimertinib was immediately discontinued, and intravenous methylprednisolone along with oral cetirizine treatment was initiated. After 8 days since discontinuation of osimertinib, the patient's skin purpura completely subsided.Subsequently, she was switched to almonertinib for treatment. We also conducted a literature review cutaneous vasculitis induced by osimertinib and other EGFR-TKIs. We hope to provide some safety alert information for clinical practice and recommend enhanced monitoring during the medication process.

    Keywords: Adverse Drug Reaction, Cutaneous Vasculitis, Osimertinib, EGFR-TKIs, case report

    Received: 06 Nov 2024; Accepted: 03 Jan 2025.

    Copyright: © 2025 Zhang, Ling, Wang, Chen and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Mingzhu Ling, Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310005, Zhejiang Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.